Profile / Biopharma
Phil Vickers
He spent 30 years at the big houses. Now he runs a 23-person biotech that is trying to decide which of your cells live and which do not.
He spent 30 years at the big houses. Now he runs a 23-person biotech that is trying to decide which of your cells live and which do not.
Solu Therapeutics occupies a corner of Eli Lilly's new Boston R&D building, which is convenient because Eli Lilly is now an investor. Phil Vickers moved his 23-person company into Lilly Gateway Labs in August 2024. Eight months later Lilly wrote a check into the Series A. The landlord-to-shareholder pipeline is, if nothing else, efficient.
The company is trying to solve a problem antibodies are bad at. Antibodies are big proteins. Some of the cell-surface targets that matter most in disease sit in deep, awkward pockets. An antibody cannot get in. So Solu is building small-molecule chimeras: a warhead on one end, a targeting handle on the other, held together by a linker. Point it at a cell you want gone. Kill only that cell.
They have two flavors of this. CyTAC, the cytotoxicity targeting chimera, hauls a payload into the cell and kills it. TicTAC, the therapeutic index control targeting chimera, is a version tuned for a wider safety margin. Both are small molecules pretending to be antibody-drug conjugates without the antibody. Vickers, who has a Ph.D. in biochemistry from the University of Toronto and a postdoc at the National Cancer Institute, is the sort of CEO who reads the pharmacokinetic data himself.
The lead program is STX-0712, aimed at chronic myelomonocytic leukemia. CMML is rare and there are almost no options. Solu dosed the first patient in a Phase 1 trial in April 2025, on the same day it announced closing $41 million in Series A funding from Eli Lilly, Pappas Capital, Biovision Ventures, Hengdian Group Capital and the Leukemia & Lymphoma Society Therapy Acceleration Program. Two press releases stapled together. Very good timing, or very good scheduling.
Vickers took the CEO chair in September 2023, replacing co-founder David Donabedian. In the 19 months that followed, the company went from seed-stage to clinical-stage. This is the second act biotech CEOs rarely get. Vickers is on his third: he ran Northern Biologics, then Faze Medicines, and now Solu. Before any of that, he was Global Head of R&D at Shire Pharmaceuticals, which is a real job with a real budget. He walked away from it to run smaller ships, and he keeps doing so.
A small molecule with a killing payload on one end and a targeting handle on the other. Point it at a disease-driving cell. The cell dies. Neighboring cells do not.
Same idea, wider margin of safety. Tuned so the therapeutic dose sits comfortably below the toxic one. Useful when the target is on cells you kind of need.
Vickers sits on the scientific advisory board of PTEN Research, a UK foundation working on a rare tumor-suppressor syndrome. He has also served on the board of AVROBIO, a gene therapy company. Both are useful vantage points for a CEO whose company is trying to build precision medicine tools.
Ph.D. in biochemistry from the University of Toronto. Postdoctoral training at the National Cancer Institute in Bethesda, Maryland. He is not a business school CEO who found biology later. He is the other kind.
Across the four big-pharma stops, he has worked on small molecules and biologics, in oncology, immunology, inflammation, cardiovascular disease and neurodegeneration. Solu is oncology first, but the platform points at inflammation and immunology as the next chapters.
CMML is not the largest market a first program could choose. It is chosen because there are almost no options. A CEO who came up through Shire, which built itself on rare disease, is unlikely to have picked it by accident.
"In the short period since our initial seed funding, Solu Therapeutics has rapidly advanced to a clinical-stage company targeting areas of high unmet medical need for patients." - On the Series A close, April 2025
"These technologies have demonstrated an unprecedented ability to unlock high-value cell surface targets that are beyond the reach of traditional antibodies, making it possible to eliminate disease-driving cells with greater precision and efficacy." - On CyTAC and TicTAC, April 2025
Solu was valued around $100M after the Series A closed, according to Vickers.
Existing investors stayed in for the A. That includes the seed backers who bet before there was a molecule in humans.
The Leukemia & Lymphoma Society's Therapy Acceleration Program joined the round. LLS invests where it wants patients treated.
Solu's four listed keywords include "mast cells," "pathogenic monocytes" and "GPCR deep pocket targeting." That last phrase is a pitch and a technical challenge in one line.
Vickers took over from Solu co-founder David Donabedian, who moved out of the CEO role in September 2023.
Merck. Pfizer. Boehringer-Ingelheim. Shire. That is the top-half of biopharma name-checked in one CV.
Philip J. Vickers is the President and CEO of Solu Therapeutics, a Boston clinical-stage biotech he has led since September 2023.
Solu develops small-molecule "chimeras" (CyTAC and TicTAC platforms) that deliver cytotoxic payloads to disease-driving cells, starting with hematologic cancers.
Solu's lead program. A Phase 1 trial began dosing patients with chronic myelomonocytic leukemia (CMML) in April 2025.
He was CEO at Faze Medicines and Northern Biologics, and held R&D leadership roles at Shire, Boehringer-Ingelheim, Pfizer and Merck.
A Ph.D. in Biochemistry from the University of Toronto and a postdoctoral fellowship at the National Cancer Institute in Bethesda, Maryland.